These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 8610089)

  • 21. The clinical and economic burden of obesity in a managed care setting.
    Oster G; Edelsberg J; O'Sullivan AK; Thompson D
    Am J Manag Care; 2000 Jun; 6(6):681-9. PubMed ID: 10977477
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The economic burden of depression in 1990.
    Greenberg PE; Stiglin LE; Finkelstein SN; Berndt ER
    J Clin Psychiatry; 1993 Nov; 54(11):405-18. PubMed ID: 8270583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors accounting for the rise in health-care spending in the United States: the role of rising disease prevalence and treatment intensity.
    Thorpe KE
    Public Health; 2006 Nov; 120(11):1002-7. PubMed ID: 17030050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Examining costs of chronic conditions in a Medicaid population.
    Garis RI; Farmer KC
    Manag Care; 2002 Aug; 11(8):43-50. PubMed ID: 12232928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sex differences in treatment patterns of six chronic diseases: an analysis from the German statutory health insurance.
    Stock SA; Stollenwerk B; Redaelli M; Civello D; Lauterbach KW
    J Womens Health (Larchmt); 2008 Apr; 17(3):343-54. PubMed ID: 18338965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema.
    Wilson L; Devine EB; So K
    Respir Med; 2000 Mar; 94(3):204-13. PubMed ID: 10783930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The economic value of reductions in gonorrhea and syphilis incidence in the United States, 1990-2003.
    Chesson HW; Gift TL; Pulver AL
    Prev Med; 2006 Nov; 43(5):411-5. PubMed ID: 16901533
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence, utilization, and costs associated with acute respiratory conditions, United States, 1980.
    Harlan WR; Murt HA; Thomas JW; Lepkowski JM; Guire KE; Parsons PE; Berki SE; Landis JR
    Natl Med Care Util Expend Surv C; 1986 Sep; (4):1-63. PubMed ID: 10313514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The joint impact of cardiovascular risk factors upon medical costs.
    Ohmori-Matsuda K; Kuriyama S; Hozawa A; Nakaya N; Shimazu T; Tsuji I
    Prev Med; 2007 Apr; 44(4):349-55. PubMed ID: 17289136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and medicare populations: A data analysis.
    Huse DM; Song X; Ozminkowski RJ; Maguire J; Williams SA; Borok GM; McDonough K
    Clin Ther; 2006 Sep; 28(9):1425-42. PubMed ID: 17062315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The economic burden of chronic cardiovascular disease for major insurers.
    Trogdon JG; Finkelstein EA; Nwaise IA; Tangka FK; Orenstein D
    Health Promot Pract; 2007 Jul; 8(3):234-42. PubMed ID: 17606951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cost of diabetes in adults in Australia.
    Lee CM; Colagiuri R; Magliano DJ; Cameron AJ; Shaw J; Zimmet P; Colagiuri S
    Diabetes Res Clin Pract; 2013 Mar; 99(3):385-90. PubMed ID: 23298663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic costs of diabetes in the US in 2002.
    Hogan P; Dall T; Nikolov P;
    Diabetes Care; 2003 Mar; 26(3):917-32. PubMed ID: 12610059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population.
    Sasser AC; Rousculp MD; Birnbaum HG; Oster EF; Lufkin E; Mallet D
    Womens Health Issues; 2005; 15(3):97-108. PubMed ID: 15894195
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association.
    Eyre H; Kahn R; Robertson RM; Clark NG; Doyle C; Hong Y; Gansler T; Glynn T; Smith RA; Taubert K; Thun MJ; ; ;
    Circulation; 2004 Jun; 109(25):3244-55. PubMed ID: 15198946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk-factor clustering and cardiovascular disease risk in hypertensive patients.
    Weycker D; Nichols GA; O'Keeffe-Rosetti M; Edelsberg J; Khan ZM; Kaura S; Oster G
    Am J Hypertens; 2007 Jun; 20(6):599-607. PubMed ID: 17531915
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The obesity-driven rising costs of type 2 diabetes in Australia: projections from the Fremantle Diabetes Study.
    Davis WA; Knuiman MW; Hendrie D; Davis TM
    Intern Med J; 2006 Mar; 36(3):155-61. PubMed ID: 16503950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost impact of COPD in Japan: opportunities and challenges?
    Nishimura S; Zaher C
    Respirology; 2004 Nov; 9(4):466-73. PubMed ID: 15612957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Costs of metabolic syndrome-related diseases induced by obesity in Taiwan.
    Fu T; Wen T; Yeh P; Chang H
    Obes Rev; 2008 Mar; 9 Suppl 1():68-73. PubMed ID: 18307702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The estimated costs and savings of medical nutrition therapy: the Medicare population.
    Sheils JF; Rubin R; Stapleton DC
    J Am Diet Assoc; 1999 Apr; 99(4):428-35. PubMed ID: 10207394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.